These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31797578)

  • 1. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
    Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
    Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
    German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
    Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
    Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
    Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
    Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
    Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
    Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
    Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
    Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis.
    Timmers M; Sinha V; Darpo B; Smith B; Brown R; Xue H; Ferber G; Streffer J; Russu A; Tritsmans L; Solanki B; Bogert J; Van Nueten L; Salvadore G; Nandy P
    J Clin Pharmacol; 2018 Jul; 58(7):952-964. PubMed ID: 29505101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Sonnichsen D
    Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
    McCrea J; Mostoller K; Mahon C; Liu C; Liu F; Zajic S; Panebianco D; Chakravarthy M; Brandquist C; Gutierrez M; Stoch SA
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):861-870. PubMed ID: 31175709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
    Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L
    Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
    Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
    Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.